(Press-News.org) LOS ANGELES—January 26, 2025—As contemporary surgical practice continues to evolve, patients who undergo surgical lung volume reduction (LVRS) for advanced emphysema may survive longer and with fewer complications than they did in the past—and they may even fare better than those who opt for endobronchial valve (EBV) placement.
At the 2025 Society of Thoracic Surgeons (STS) Annual Meeting, researchers presented risk-adjusted findings that shed new light on treatments for severe emphysema. Despite having shorter hospital stays, lower hospital charges, and lower Elixhauser Comorbidity Index scores—a tool that quantifies pre-existing conditions and how they affect treatment outcomes—investigators found that patients who underwent EBV placement ultimately had more complications and higher longitudinal risk of death than those who received LVRS.
“The standard treatment using bronchodilators is typically sufficient for most patients, but often, the disease is very severe and has no definitive therapeutic options,” said lead study author J. W. Awori Hayanga, MD, MPH, professor of thoracic surgery, Department of Cardiovascular and Thoracic Surgery, West Virginia University.
“Lung transplantation is not always a durable solution because of the shortage of donors compared to the demand for organs,” Dr. Hayanga explained. “The potential of surgical volume reduction was duly explored in the late 1990s in patients with severe emphysema. The surgical approach, however, did not gain broad popularity because of the high mortality of 8% and the small group of patients believed to benefit from the procedure.”
Early trials in the 2010s tested EBVs as an alternative option, said Dr. Hayanga, and after the valves received FDA approval in 2018, their use and popularity has grown rapidly as a treatment for patients with conditions like chronic obstructive pulmonary disorder (COPD).
Long-term data on how patients with severe emphysema fared after EBV placement, however, remain limited. Dr. Hayanga’s team examined mortality and procedure-related complications in patients with advanced emphysema, using doubly-robust risk-adjusted models that compared patient outcomes after EBV placement versus after LVRS.
“We observed that patients undergoing EBV placement have higher occurrences of various complications over time, often need a greater number of interventions, and even suffer higher mortality compared to those undergoing LVRS in contemporary surgical practice, where techniques have become much less invasive than they were 20 years ago when surgical options were first evaluated,” said Dr. Hayanga.
The team examined data from the Centers for Medicare and Medicaid Services inpatient claims database, evaluating all beneficiaries with severe emphysema undergoing either LVRS or EBV between January 1, 2019, and December 31, 2022. They included a total of 3,219 patients; 2,378 received LVRS and 841 received EBV placement.
Prior to risk adjustment, EBV recipients had lower Elixhauser comorbidity scores, shorter lengths of hospital stay, and lower hospital charges compared to those who underwent LVRS. Most LVRS procedures (1,897) were minimally invasive video-assisted thoracoscopic or robotic surgeries, while 481 were open surgeries.
“Medicare beneficiaries who undergo EBV present with fewer comorbidities, but after risk adjustment they have higher mortality and procedure-related morbidity than those undergoing LVRS,” Dr. Hayanga said.
The team said that these results suggest the need to revisit multidisciplinary decision-making about the role of surgery over bronchoscopic interventional therapy in the management of advanced emphysema.
“Outcomes after surgery were better than previously reported and were often better than those after valve placement,” Dr. Hayanga observed. “It is likely that patients do far better after surgery than they used to.”
# # #
About STS
Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 7,800 cardiothoracic surgeons, researchers, and allied healthcare professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society’s mission is to improve the lives of patients with cardiothoracic diseases.
END
LOS ANGELES—January 25, 2025—A late-breaking study presented today at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for patients aged 60 and younger compared to bioprosthetic valves. The study, leveraging data from the STS Adult Cardiac Surgery Database (ACSD), offers the most comprehensive analysis to date of prosthetic valve outcomes, encompassing over 100,000 patients.
The study addressed a critical question ...
LOS ANGELES—January 25, 2025 New research presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that anatomic lung resections, such as lobectomy and segmentectomy, are associated with improved long-term survival compared to wedge resection for patients with early-stage non-small cell lung cancer (NSCLC).
The study analyzed outcomes for more than 32,000 stage 1A NSCLC patients using data from the STS General Thoracic Surgery Database (STS GTSD) with long-term follow-up linked to the National Death Index and Centers ...
SAN FRANCISCO – Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.
The findings, presented today at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Annual Symposium and published in Nature Medicine, demonstrated a 60.9% overall response rate (ORR) with the three-drug combination ...
Boston – A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment. The analysis showed that patients with positive blood tests for circulating tumor DNA (ctDNA) had worse outcomes in general, but those who were treated with celecoxib, a non-steroidal anti-inflammatory drug, experienced significantly improved disease-free survival.
“This is one of the first studies to show that ctDNA status has predictive utility in terms of selecting ...
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to treatment after surgery might help those who still have traces of cancer in their blood. The analysis showed that patients with signs of cancer in their blood measured by Signatera™, a circulating tumor DNA (ctDNA) test, tended to have worse outcomes. However, those who took celecoxib after surgery had a much better chance of staying cancer-free. These results are being presented in a late-breaking ...
Tokyo, Japan – Researchers from Tokyo Metropolitan University have developed a new dye that can strongly absorb second near-IR radiation and transform it to heat. Starting with a dye from the bile pigment family, they designed a unique ring structure which can bind rhodium and iridium. Measurements and modeling revealed strong second near-IR absorptions and exceptional photostability. Second near-IR waves easily penetrate human tissue; the new dye may be applied in deep tissue therapies and imaging.
The second near-IR region of the electromagnetic spectrum (1000-1700 nanometers) ...
Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help restore vision in individuals with multiple sclerosis (MS) and other neurological conditions that damage neurons.
The study was published this week in the journal Nature Communications.
The drug, LL-341070, enhances the brain's ability to repair damaged myelin— the protective sheath around nerve fibers. Damage to myelin is a hallmark of diseases like MS, as well as a natural consequence of aging, often resulting in vision loss, loss of motor skills, ...
Complex organisms, thousands of times smaller than a grain of sand, can shape massive ecosystems and influence the fate of Earth's climate, according to a new study.
Researchers from Arizona State University, along with their colleagues from the National University of the Peruvian Amazon, have identified an unknown family of microbes uniquely adapted to the waterlogged, low-oxygen conditions of tropical peatlands in Peru’s northwestern Amazonian rainforest.
The new research shows these microbes have a dual role in the carbon cycle and the potential to either ...
CLEVELAND – University Hospitals is now offering endoscopic spine surgery for patients needing treatment for back pain due to herniated discs in their spine. Xiaofei (Sophie) Zhou, MD, completed Arthrex's Endoscopic Spine Training course to bring this advanced procedure to the health system and recently completed the first endoscopic discectomy utilizing Arthrex technology at UH. The health system is the only one in the greater Cleveland area offering this type of ultra-minimally invasive surgery.
Arthrex's technology allows surgeons to remove the ...
Reston, VA (January 24, 2025)—The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for the use of fibroblast activation protein (FAP) PET. Published in the January issue of The Journal of Nuclear Medicine, the procedure standard/practice guideline was developed to assist providers in recommending and performing FAP PET, as well as interpreting and reporting results of the imaging studies.
FAP is a transmembrane protein expressed on both cancer-associated fibroblasts and on normal activated fibroblasts involved in wound healing and ...
